A tentative treatment with Antineoplaston AS2-1 was carried out in a group of 16 patients with subacute sclerosing panencephalitis (SSPE). Most patients were in phase II of SSPE (after Jabbour) with mean disease duration 6.4 months. Their age ranged from 13 to 28 years. They were given for 6 months 15 capsules of Antineoplaston AS2-1 and 6 tablets of isoprinosine daily. Despite that treatment progression was observed of the disturbances of higher nervous functions, less so of motor functions. The treatment had no effect on MRI results, EEG and antimeasles antibodies levels. No adverse effects were observed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antineoplaston as2-1
12
treatment antineoplaston
8
subacute sclerosing
8
[assessment early
4
treatment
4
early treatment
4
as2-1 subacute
4
sclerosing panencephalitis]
4
panencephalitis] tentative
4
tentative treatment
4

Similar Publications

Tectal glioma is a midbrain tumor. The patient generally presents with symptoms related to increased intracranial pressure and requires treatment for hydrocephalus. No effective pharmacological treatments have yet been introduced.

View Article and Find Full Text PDF

Background: Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. Antineoplaston A10 and AS2-1 reportedly control neoplastic growth and do not significantly inhibit normal cell growth. Antineoplastons contain 3-phenylacetylamino-2, 6-piperidinedione (A10), phenylacetylglutamine plus phenylacetylisoglutamine (A10-I), and phenylacetylglutamine plus phenylacetate (AS2-1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!